A 45-year-old woman has high genomic risk on MammaPrint despite favourable clinical features. What does the MINDACT trial suggest?

Question

Accepted Answer

High genomic risk identifies patients who benefit from chemotherapy even when clinical risk appears low

Answer

All breast cancer patients need chemotherapy as the preferred next management strategy

Answer

The assay replaces ER testing as the preferred next management strategy in this patient

Answer

MammaPrint is only for TNBC as the preferred next management strategy in this patient

Answer

MammaPrint predicts endocrine resistance as the preferred next management strategy in this patient

Breast Cancer — SCE Medical Oncology MCQ